Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | GPR119 | Q8TDV5 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | PDK2 | Q15119 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.44 |
| ▸ | DPP4 | P27487 | 1/20 | 0.44 |
| ▸ | SUV39H2 | Q9H5I1 | 4/20 | 0.43 |
| ▸ | CXCR2 | P25025 | 1/20 | 0.42 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL671649 | 0.89 | LMNA (0.46) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL20140111 | 0.88 | MAPT (0.54) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL670084 | 0.83 | DPP4 (0.39) | LMNAMAPTALDH1A1GPR119DPP4 | |
| SCHEMBL671902 | 0.81 | ALDH1A1 (0.48) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL24379385 | 0.81 | MAPT (0.56) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL15754287 | 0.81 | ALDH1A1 (0.52) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL31623073 | 0.81 | MAPT (0.52) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL29707428 | 0.80 | GPR119 (0.49) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL28505612 | 0.80 | MAPT (0.51) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 | |
| SCHEMBL4941010 | 0.80 | LMNA (0.51) | LMNAMAPTALDH1A1GPR119SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9040545-B2 | Heterocyclyl pyrazolopyrimidine analogues as selective JAK inhibitors | CELLZOME LIMITED (GB) | 2015-05-26 | — | — | US | disclosed |
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2013-07-25 | — | — | US | disclosed |
| EP-2606050-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | Cellzome Limited (GB) | 2013-06-26 | — | — | EP | disclosed |
| WO-2012022681-A2 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | CELLZOME LIMITED (GB) | 2012-02-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130190292-A1 | HETEROCYCLYL PYRAZOLOPYRIMIDINE ANALOGUES AS SELECTIVE JAK INHIBITORS | JAK1, JAK3, JAK2 | LMNA 4624/4885MAPT 4493/4885ALDH1A1 2345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.